[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. 2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Feng, X., Feng, G.Y., Tao, J., et al. (2023) Comparison of Different Ad-juvant Therapy Regimen Efficacies in Patients with High Risk of Recurrence after Radical Resection of Hepatocellular Carcinoma. Journal of Cancer Research and Clinical Oncology, 149, 10505-10518. https://doi.org/10.1007/s00432-023-04874-0
|
[3]
|
Dai, H.T., Wang, S.T., Chen, B., et al. (2022) MicroRNA-375 Inhibits the Malignant Behaviors of Hepatic Carcinoma Cells by Targeting NCAPG2. Neoplasma, 69, 16-27. https://doi.org/10.4149/neo_2021_210318N358
|
[4]
|
He, J., Wu, J., Dong, S., et al. (2023) Exosome-Encapsulated miR-31, miR-192, and miR-375 Serve as Clinical Biomarkers of Gastric Cancer. Journal of Oncology, 2023, Article ID: 7335456. https://doi.org/10.1155/2023/7335456
|
[5]
|
Moorthy, R.K., Srinivasan, C., Kannan, M. and Velanganni Arockiam, A.J. (2023) Deregulation of miR-375 Inhibits HOXA5 and Promotes Migration, Invasion, and Cell Prolifera-tion in Breast Cancer. Applied Biochemistry and Biotechnology, 195, 4503-4523. https://doi.org/10.1007/s12010-023-04375-3
|
[6]
|
Xu, J., Li, B., Song, W., et al. (2021) Tumor Suppressor Func-tions of miRNA-375 in Nasopharyngeal Carcinoma through Inhibition of Ubiquitin-Specific Protease 1 Expression. The International Journal of Biochemistry & Cell Biology, 141, Article ID: 106092. https://doi.org/10.1016/j.biocel.2021.106092
|
[7]
|
Liu, L., Xiao, C. and Sun, Q. (2022) MiRNA-375 Inhibits Reti-noblastoma Progression through Targeting ERBB2 and Inhibiting MAPK1/MAPK3 Signalling Pathway. Cutaneous and Ocular Toxicology, 41, 1-10.
https://doi.org/10.1080/15569527.2021.1994587
|
[8]
|
Xu, W., Lou, W. and Mei, L. (2023) A Key Regulatory Loop AK4P1/miR-375/SP1 in Pancreatic Adenocarcinoma. Epigenetics, 18, Article ID: 2148433. https://doi.org/10.1080/15592294.2022.2148433
|
[9]
|
Chen, J., Cai, Z., Hu, J., et al. (2023) MicroRNA-375 in Ex-tracellular Vesicles—Novel Marker for Esophageal Cancer Diagnosis. Medicine, 102, e32826. https://doi.org/10.1097/MD.0000000000032826
|
[10]
|
Liu, Y., Yang, C., Chen, S., et al. (2023) Cancer-Derived Exosomal miR-375 Targets DIP2C and Promotes Osteoblastic Metastasis and Prostate Cancer Progression by Regulating the Wnt Signaling Pathway. Cancer Gene Therapy, 30, 437-449. https://doi.org/10.1038/s41417-022-00563-1
|
[11]
|
Wei, J., Lu, Y., Wang, R., et al. (2021) MicroRNA-375: Poten-tial Cancer Suppressor and Therapeutic Drug. Bioscience Reports, 41, BSR20211494. https://doi.org/10.1042/BSR20211494
|
[12]
|
Peng, C., Ye, Y., Wang, Z., et al. (2019) Circulating microRNAs for the Diagnosis of Hepatocellular Carcinoma. Digestive and Liver Disease, 51, 621-631. https://doi.org/10.1016/j.dld.2018.12.011
|
[13]
|
Solís-Toro, D., Mosquera Escudero, M. and García-Perdomo, H.A. (2022) Association between Circulating MicroRNAs and the Metabolic Syndrome in Adult Populations: A Systematic Review. Diabetes & Metabolic Syndrome, 16, Article ID: 102376. https://doi.org/10.1016/j.dsx.2021.102376
|
[14]
|
Zhong, S., Golpon, H., Zardo, P. and Borlak, J. (2021) MiRNAs in Lung Cancer. A Systematic Review Identifies Predictive and Prognostic miRNA Candidates for Precision Medicine in Lung Cancer. Translational Research, 230, 164-196. https://doi.org/10.1016/j.trsl.2020.11.012
|
[15]
|
Zhan, B., Lu, D., Luo, P. and Wang, B.L. (2016) Prognostic Value of Expression of MicroRNAs in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Clinical Laboratory, 62, 2203-2211.
https://doi.org/10.7754/Clin.Lab.2016.160426
|
[16]
|
Gan, J., Liu, S., Zhang, Y., et al. (2022) MicroRNA-375 Is a Therapeutic Target for Castration-Resistant Prostate Cancer through the PTPN4/STAT3 Axis. Experimental & Molecular Medicine, 54, 1290-1305.
https://doi.org/10.1038/s12276-022-00837-6
|
[17]
|
Tang, W., Li, G.S., Li, J.D., et al. (2020) The Role of Upregu-lated miR-375 Expression in Breast Cancer: An in Vitro and in Silico Study. Pathology, Research and Practice, 216, Ar-ticle ID: 152754.
https://doi.org/10.1016/j.prp.2019.152754
|
[18]
|
He, Y., Jin, J., Wang, L., et al. (2017) Evaluation of miR-21 and miR-375 as Prognostic Biomarkers in Oesophageal Cancer in High-Risk Areas in China. Clinical & Experimental Me-tastasis, 34, 73-84.
https://doi.org/10.1007/s10585-016-9828-4
|
[19]
|
Li, L., Jia, L. and Ding, Y. (2018) Upregulation of miR-375 In-hibits Human Liver Cancer Cell Growth by Modulating Cell Proliferation and Apoptosis via Targeting ErbB2. Oncology Letters, 16, 3319-3326.
https://doi.org/10.3892/ol.2018.9011
|
[20]
|
Mirzaei, H.R., Sahebkar, A., Mohammadi, M., et al. (2016) Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers. Current Pharmaceutical De-sign, 22, 5257-5269.
https://doi.org/10.2174/1381612822666160303110838
|
[21]
|
Jiang, Y.Q., Wang, Z.X., Deng, Y.N., et al. (2019) Efficacy of Hepatic Resection vs. Radiofrequency Ablation for Patients with Very-Early-Stage or Early-Stage Hepatocel-lular Carcinoma: A Population-Based Study with Stratification by Age and Tumor Size. Frontiers in Oncology, 9, Article 113. https://doi.org/10.3389/fonc.2019.00113
|
[22]
|
Ko, K.L., Mak, L.Y., Cheung, K.S. and Yuen, M.F. (2020) Hepatocellular Carcinoma: Recent Advances and Emerging Medical Therapies. F1000Research, 9, Article 620. https://doi.org/10.12688/f1000research.24543.1
|
[23]
|
王靖超, 安斌斌, 王志鑫, 等. 晚期肝细胞癌的免疫治疗现状综述[J]. 临床医学进展, 2021, 11(12): 5740-5746.
|
[24]
|
Vogel, A. and Saborowski, A. (2020) Current Strategies for the Treatment of Intermediate and Advanced Hepatocellular Carcinoma. Cancer Treatment Reviews, 82, Article ID: 101946. https://doi.org/10.1016/j.ctrv.2019.101946
|
[25]
|
Kudo, M., Finn, R.S., Qin, S., et al. (2018) Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. The Lancet, 391, 1163-1173.
https://doi.org/10.1016/S0140-6736(18)30207-1
|
[26]
|
Yoo, C., Park, J.W., Kim, Y.J., et al. (2019) Multicenter Retrospective Analysis of the Safety and Efficacy of Regorafenib after Progression on Sorafenib in Korean Patients with Hepatocellular Carcinoma. Investigational New Drugs, 37, 567-572. https://doi.org/10.1007/s10637-018-0707-5
|
[27]
|
Trojan, J. (2020) Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Drugs, 80, 1203-1210. https://doi.org/10.1007/s40265-020-01361-5
|
[28]
|
Kelley, R.K., Rimassa, L., Cheng, A.L., et al. (2022) Cabozan-tinib plus Atezolizumab versus Sorafenib for Advanced Hepatocellular Carcinoma (COSMIC-312): A Multicentre, Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology, 23, 995-1008. https://doi.org/10.1016/S1470-2045(22)00326-6
|
[29]
|
Casak, S.J., Donoghue, M., Fashoyin-Aje, L., et al. (2021) FDA Approval Summary: Atezolizumab plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma. Clinical Cancer Research, 27, 1836-1841. https://doi.org/10.1158/1078-0432.CCR-20-3407
|
[30]
|
Yang, S., Wang, M., Yang, L., et al. (2020) Mi-croRNA-375 Targets ATG14 to Inhibit Autophagy and Sensitize Hepatocellular Carcinoma Cells to Sorafenib. Onco-Targets and Therapy, 13, 3557-3570.
https://doi.org/10.2147/OTT.S247655
|
[31]
|
Li, D., Wang, T., Sun, F.F., et al. (2021) MicroRNA-375 Represses Tumor Angiogenesis and Reverses Resistance to Sorafenib in Hepatocarcinoma. Cancer Gene Therapy, 28, 126-140. https://doi.org/10.1038/s41417-020-0191-x
|
[32]
|
Liu, A.M., Poon, R.T. and Luk, J.M. (2010) MicroRNA-375 Targets Hippo-Signaling Effector YAP in Liver Cancer and Inhibits Tumor Properties. Biochemical and Biophysical Re-search Communications, 394, 623-627.
https://doi.org/10.1016/j.bbrc.2010.03.036
|